These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 5160871)
21. Yishou jiangzhi (de-blood-lipid) tablets in the treatment of hyperlipemia. Guan Y; Zhao S J Tradit Chin Med; 1995 Sep; 15(3):178-9. PubMed ID: 8569253 [TBL] [Abstract][Full Text] [Related]
22. [Hyperlipidemia in the elderly]. Kawano M Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980 [TBL] [Abstract][Full Text] [Related]
23. Studies of the uricosuric action of the hypolipidemic drug halofenate. Ravenscroft PJ; Sands JM; Emmerson BT Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262 [No Abstract] [Full Text] [Related]
24. The effect of dextran on plasma lipids. A study on patient with essential hypercholesterolemia or hyperlipemia. Blohmé G; Kerstell J; Svanborg A Acta Med Scand; 1968 May; 183(5):481-5. PubMed ID: 5703642 [No Abstract] [Full Text] [Related]
25. [Jiangzhi koufu ye in the treatment of essential hyperlipemia]. Liu J; Chang JJ Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Nov; 13(11):658-60, 643-4. PubMed ID: 8155940 [TBL] [Abstract][Full Text] [Related]
30. Comparative hypolipidaemic effectiveness of gum guggulu (Commiphora mukul) fraction 'A', ethyl-P-chlorophenoxyisobutyrate and Ciba-13437-Su. Malhotra SC; Ahuja MM Indian J Med Res; 1971 Oct; 59(10):1621-32. PubMed ID: 5159000 [No Abstract] [Full Text] [Related]
31. Clinical trial of gugulipid--a new hypolipidemic agent of plant origin in primary hyperlipidemia. Agarwal RC; Singh SP; Saran RK; Das SK; Sinha N; Asthana OP; Gupta PP; Nityanand S; Dhawan BN; Agarwal SS Indian J Med Res; 1986 Dec; 84():626-34. PubMed ID: 3552974 [No Abstract] [Full Text] [Related]
32. [Hyperlipemia as a risk factor in ischemic heart disease]. Hashimoto T; Kobayashi M; Igarashi H; Niitani H Nihon Rinsho; 1975 Nov; 33(11):3179-84. PubMed ID: 1107622 [No Abstract] [Full Text] [Related]
33. [Preliminary results of an open study on the effects of DEAE-dextran on various lipid metabolism parameters in dyslipidemic subjects]. Graziani P; Leproux GB; Gavelli MS; Vitaliano E; Serra T; Santini G Clin Ter; 1989 Nov; 131(3):183-7. PubMed ID: 2482151 [TBL] [Abstract][Full Text] [Related]
34. Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437). Fellin R; Fedele D; Bagnariol G; Pagnan A; Crepaldi G Atherosclerosis; 1973; 17(3):383-8. PubMed ID: 4577009 [No Abstract] [Full Text] [Related]
35. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)]. Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781 [No Abstract] [Full Text] [Related]
36. [Treatment of coronary arteriosclerosis depending on the nature of lipid metabolism disorders]. Anisimov VE; Semavin IE Klin Med (Mosk); 1975 Jul; 53(7):66-9. PubMed ID: 1206996 [No Abstract] [Full Text] [Related]
37. Management of the elderly patient with hyperlipidaemia: recent concerns. Kalantzi KI; Milionis HJ; Goudevenos IA Hellenic J Cardiol; 2006; 47(2):93-9. PubMed ID: 16752529 [No Abstract] [Full Text] [Related]